PreppinPeppers › Facts › Lab article
Adipotide: Reference Overview and Reconstitution Notes
Machine-readable facts for this Lab article. The full page is https://www.preppinpeppers.com/blogs/the-lab/adipotide.
TL;DR
Adipotide, also written FTPP, is a synthetic chimeric peptidomimetic that joins a homing sequence targeting blood vessels of white adipose tissue. Lab notes.
Facts Index
| Fact ID | Category | Entity | Attribute | Value | Source |
|---|---|---|---|---|---|
| adipotide:title | identity | Adipotide: Reference Overview and Reconstitution Notes | title | Adipotide: Reference Overview and Reconstitution Notes | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:published | identity | Adipotide: Reference Overview and Reconstitution Notes | published | 2026-08-18 | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:author | identity | Adipotide: Reference Overview and Reconstitution Notes | author | Preppin' Peppers Editorial Team | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:topics | identity | Adipotide: Reference Overview and Reconstitution Notes | topics | reference, research | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:summary | content | Adipotide: Reference Overview and Reconstitution Notes | summary | Adipotide, also written FTPP, is a synthetic chimeric peptidomimetic that joins a homing sequence targeting blood vessels of white adipose tissue. Lab notes. | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-1 | content | Adipotide: Reference Overview and Reconstitution Notes | section | What it is | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-2 | content | Adipotide: Reference Overview and Reconstitution Notes | section | What it is | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-3 | content | Adipotide: Reference Overview and Reconstitution Notes | section | Research context | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-4 | content | Adipotide: Reference Overview and Reconstitution Notes | section | Status | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-5 | content | Adipotide: Reference Overview and Reconstitution Notes | section | Reconstitution and handling | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-6 | content | Adipotide: Reference Overview and Reconstitution Notes | section | Status in sport | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-7 | content | Adipotide: Reference Overview and Reconstitution Notes | section | Related reading | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:section-9 | content | Adipotide: Reference Overview and Reconstitution Notes | section | What the research community gets wrong about Adipotide | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:source-pubmed-ncbi-nlm-nih-gov | source | Adipotide: Reference Overview and Reconstitution Notes | cites | Barnhart et al., Sci Transl Med 2011: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:source-clinicaltrials-gov | source | Adipotide: Reference Overview and Reconstitution Notes | cites | ClinicalTrials.gov NCT01262664 (Phase 1, terminated, first posted 2010-12-17): A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity - clinicaltrials.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:source-www-uniprot-org | source | Adipotide: Reference Overview and Reconstitution Notes | cites | UniProtKB P35232: Prohibitin 1 (PHB1, Homo sapiens), UniProt release 2026-03 - www.uniprot.org | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
| adipotide:source-pubmed-ncbi-nlm-nih-gov-2 | source | Adipotide: Reference Overview and Reconstitution Notes | cites | Hossen et al., J Control Release 2013: A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/adipotide) (evidence) |
FAQ
- Has Adipotide been reviewed by regulators?
- No. It is not approved by any regulator and is not a licensed product; its only registered Phase I trial was terminated in 2019 at the principal investigator's request.
- What does Adipotide target?
- It binds prohibitin on the vasculature supplying white adipose tissue and triggers cell death there, reducing the blood supply to that tissue. It does not act on appetite signalling the way incretin compounds do.
- Why did development stop?
- ClinicalTrials.gov records NCT01262664 as terminated in January 2019 at the principal investigator's request; no other reason is given there. Kidney tubular changes had already been observed, dose-dependently, in the 2011 primate study.